Project Grant R21AG102450
- The National Institute on Aging awarded the University of Pittsburgh $428,123 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mechanisms of chondrocyte aging and cartilage degeneration. The project, titled "Suppressing Aging-Associated Increase of GATA4 Levels to Rejuvenate Old Chondrocytes," addresses how chondrocytes—the primary cell type in articular cartilage—exhibit reduced regenerative capacity and increased inflammatory responsiveness as they...
- The National Institute on Aging, part of the Department of Health and Human Services National Institutes of Health, awarded $1.373 million to the University of California, Davis on May 15, 2026 under the Aging Research program (CFDA 93.866) to investigate skeletal stem cell-based cartilage regeneration in aged and osteoarthritic joints. The recipient will elucidate cellular dynamics and molecular mechanisms underlying skeletal stem cell (SSC)-mediated cartilage repair, with particular focus on...
- The National Institute on Aging awarded the University of Pennsylvania $164,190 under the Aging Research program (CFDA 93.866) on November 27, 2025, to investigate mechanisms by which non-muscle myosin II inhibition prevents osteoarthritis progression through modulation of synovial mechanobiology. The research addresses the pathology of synovial fibrosis in osteoarthritis by examining how fibroblast-like synoviocytes undergo myofibroblastic differentiation in response to inflammatory signaling...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded The Johns Hopkins University $427,625 for Project Grant R21AG102518 on September 1, 2026, under the Aging Research program (CFDA 93.866). The recipient will develop a human three-dimensional neuromuscular microphysiological system to model skeletal muscle aging ex vivo. The platform integrates primary human muscle stem cells from young (20–30 years) and aged (60–75 years) donors, induced pluripotent...
- The National Institute on Aging awarded the University of North Carolina at Chapel Hill $2,265,261 on July 15, 2026, under the Aging Research program (CFDA 93.866) to investigate integrin signaling mechanisms in osteoarthritis progression. The award funds basic research examining how α5β1 integrin receptor activation by fibronectin matrix degradation products initiates pathologic cellular signaling cascades that drive chronic, non-healing inflammation and progressive cartilage destruction in...
- The National Institute on Aging awarded $648,930 to the Regents of the University of California, doing business as University of California, Berkeley, on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop human stem cell-based microphysiological systems for aging research. The recipient will create a novel human aging-on-a-chip platform integrating fat and liver tissues derived from human induced pluripotent stem cells (hiPSCs) and microfluidics using serum from young...
- The National Institute on Aging awarded the University of Delaware $560,380 on January 15, 2026, under the Aging Research program (CFDA 93.866) to develop and apply a novel force-sensing universal robotic testing system for analyzing the biomechanical function of rodent joints in osteoarthritis research. The award funds in situ assessment of multi-axial knee biomechanics in healthy and injured mouse models, specifically characterizing the immediate mechanical effects of two common injury...
- The National Institute on Aging awarded New York University $708,137 on February 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate technologies for probing the biophysical properties of aging cells. The funded work centers on developing genetically encoded multimeric particles (GEMs) as high-throughput microrheology probes to measure the physical properties of cell interiors—particularly within organelles including the nucleus, cytoplasm, endoplasmic reticulum,...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $533,500 to the Buck Institute for Research on Aging on July 15, 2026, under the Aging Research program (CFDA 93.866). The award funds examination of the role of autonomic innervation in muscle stem cell aging. The research investigates the functional link between autonomic nervous system neurons and muscle stem cells using Drosophila melanogaster as a model organism. The project will refine...
- The National Institute on Aging awarded Drexel University $420,554 under Aging Research (CFDA 93.866) on September 1, 2026, to establish an integrated system for studying senescence and aging in the central nervous system. The award funds two research aims: characterization of the molecular and functional consequences of senescence in astrocyte and neuronal cultures, and evaluation of senescence impact in a multicellular context using hiPSC-derived vascularized cortical organoids. Single-cell...
The National Institute on Aging awarded the University of Pittsburgh $484,635 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop in vitro aging of cartilage in a microphysiological knee joint system. The recipient will extend the "minijoint," a microphysiological system representing critical joint tissues (cartilage, bone, synovium, adipose) and using microfluidics, to recapitulate the transition of chondrocytes from young and healthy to aged and dysfunctional. The work introduces sera from older human donors as a physiologically relevant source of age-promoting biological factors in the minijoint system. The project will employ a chondrocyte-specific transcriptomic clock, generated from gene expression data of primary chondrocytes across a wide age range, to assess the rate of in vitro aging. The long-term goal is to increase understanding of aging-associated osteoarthritis and develop interventions to halt or reverse chondrocyte aging in humans. The award funds investigator-initiated research addressing the underlying causes of chondrocyte dysfunction in aging. Unlike animal models that have failed to yield approved disease-modifying osteoarthritis drugs, this microphysiological system offers an alternative approach to understanding joint disease mechanisms in humans. Performance occurs in Pittsburgh, Pennsylvania. The period of performance extends from September 1, 2026, through August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $484.6k | 8/26/26 |